Satralizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Trial Timeline
Aug 30, 2022 → Dec 31, 2028
NCT ID
NCT05271409About Satralizumab
Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05271409. Target conditions include Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503264 | Phase 3 | Recruiting |
| NCT05271409 | Phase 3 | Recruiting |
| NCT04963270 | Phase 3 | Terminated |
Competing Products
20 competing products in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fingolimod + Placebo Comparator | Novartis | Phase 3 | 77 |
| KITE-363 + Fludarabine + Cyclophosphamide | Gilead Sciences | Phase 1 | 32 |
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| placebo (saline) + Olipudase alfa | Sanofi | Phase 2/3 | 64 |
| GZ402665 | Sanofi | Phase 2 | 51 |
| Olipudase alfa | Sanofi | Phase 1/2 | 40 |
| SAR445088 (IV) + SAR445088 (SC) | Sanofi | Phase 2 | 51 |
| olipudase alfa (GZ402665) | Sanofi | Pre-clinical | 22 |
| Riliprubart Prefilled Pen (PFP) | Sanofi | Phase 3 | 76 |
| Riliprubart + Placebo + Riliprubart + Placebo | Sanofi | Phase 3 | 76 |
| Alemtuzumab infusion | Sanofi | Approved | 84 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |
| riliprubart + Placebo + riliprubart + Placebo + IVIg + Placebo | Sanofi | Phase 3 | 76 |
| Intravenous Immunoglobulin | CSL | Pre-clinical | 22 |
| IgPro10 | CSL | Approved | 84 |
| Immune Globulin Subcutaneous (Human) | CSL | Pre-clinical | 22 |
| IgPro20 | CSL | Phase 3 | 76 |
| Hizentra | CSL | Pre-clinical | 22 |
| 10% liquid formulation of human immunoglobulin | CSL | Phase 3 | 76 |